公开(公告)号：US20240190843A1

公开(公告)日：2024-06-13

申请号：US18553214

申请日：2022-03-30

Applicant: Array BioPharma Inc.

Inventor： Katie Keaton BROWN ,  Aaron Keith GOODWIN

IPC: C07D401/14 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/506 ,  A61K31/53 ,  A61K39/00 ,  C07K16/28

CPC classification number: C07D401/14 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/506 ,  A61K31/53 ,  C07K16/2863 ,  A61K2039/505

Abstract: This Invention relates to a hemihydrate crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.

公开(公告)号：US20220289721A1

公开(公告)日：2022-09-15

申请号：US17745346

申请日：2022-05-16

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael BARBOUR ,  Katie Keaton BROWN ,  Adam Wade COOK ,  Erik James HICKEN ,  Dean Russell KAHN ,  Ellen Ruth LAIRD ,  Andrew Terrance METCALF ,  David Austin MORENO ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK ,  Brett Joseph PRIGARO ,  Li REN ,  Eugene TARLTON

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.